Abstract:BACKGROUND:Randomized controlled trials are considered the gold standard for evaluating experimental treatments but often require large sample sizes. Single-arm trials require smaller sample sizes but are subject to bias when using historical control data for comparative inferences. This article presents a Bayesian adaptive synthetic-control design that exploits historical control data to create a hybrid of a single-arm trial and a randomized controlled trial.METHODS:The Bayesian adaptive synthetic control design has two stages. In stage 1, a prespecified number of patients are enrolled in a single arm given the experimental treatment. Based on the stage 1 data, applying propensity score matching and Bayesian posterior prediction methods, the usefulness of the historical control data for identifying a pseudo sample of matched synthetic-control patients for making comparative inferences is evaluated. If a sufficient number of synthetic controls can be identified, the single-arm trial is continued. If not, the trial is switched to a randomized controlled trial. The performance of The Bayesian adaptive synthetic control design is evaluated by computer simulation.RESULTS:The Bayesian adaptive synthetic control design achieves power and unbiasedness similar to a randomized controlled trial but on average requires a much smaller sample size, provided that the historical control data patients are sufficiently comparable to the trial patients so that a good number of matched controls can be identified in the historical control data. Compared to a single-arm trial, The Bayesian adaptive synthetic control design yields much higher power and much smaller bias.CONCLUSION:The Bayesian adaptive synthetic-control design provides a useful tool for exploiting historical control data to improve the efficiency of single-arm phase II clinical trials, while addressing the problem of bias when comparing trial results to historical control data. The proposed design achieves power similar to a randomized controlled trial but may require a substantially smaller sample size.

Statistical design considerations for trials that study multiple indications

Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples

Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Precision Dose-finding Cancer Clinical Trials in the Setting of Broadened Eligibility

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility

Lessons Learned from Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer.

Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Optimal predictive probability designs for randomized biomarker-guided oncology trials

Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials

Designing clinical trials for patients who are not average

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Biomarker enrichment strategies: matching trial design to biomarker credentials

Comparative Review of Novel Model‐assisted Designs for Phase I Clinical Trials

Hierarchical Bayesian Clustering Design of Multiple Biomarker Subgroups (HCOMBS)

Comparative review of novel model-assisted designs for phase I clinical trials.

Clinical trial design: Past, present, and future in the context of big data and precision medicine